N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Price:
20.99
CNY
-0.38%
Market Closed
Market Cap:
¥8.3B
Balance Sheet
Balance Sheet Decomposition
Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co Ltd
Balance Sheet Decomposition is not available for
Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co Ltd
Balance Sheet
Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co Ltd
Currency: CNY
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
83
|
94
|
222
|
1 478
|
1 345
|
848
|
434
|
|
| Cash |
0
|
0
|
0
|
0
|
1 345
|
848
|
423
|
|
| Cash Equivalents |
83
|
94
|
222
|
1 478
|
0
|
0
|
11
|
|
| Short-Term Investments |
9
|
0
|
796
|
1 976
|
1 919
|
2 633
|
2 222
|
|
| Total Receivables |
53
|
81
|
234
|
334
|
855
|
366
|
518
|
|
| Accounts Receivables |
40
|
71
|
226
|
322
|
838
|
352
|
480
|
|
| Other Receivables |
13
|
10
|
8
|
12
|
17
|
14
|
38
|
|
| Inventory |
28
|
53
|
132
|
242
|
364
|
346
|
362
|
|
| Other Current Assets |
2
|
4
|
12
|
21
|
82
|
37
|
35
|
|
| Total Current Assets |
176
|
233
|
1 396
|
4 051
|
4 565
|
4 230
|
3 571
|
|
| PP&E Net |
28
|
35
|
134
|
343
|
785
|
836
|
741
|
|
| PP&E Gross |
28
|
35
|
134
|
343
|
785
|
836
|
741
|
|
| Accumulated Depreciation |
10
|
16
|
27
|
74
|
387
|
485
|
602
|
|
| Intangible Assets |
1
|
2
|
7
|
17
|
50
|
101
|
95
|
|
| Goodwill |
0
|
0
|
0
|
0
|
130
|
130
|
130
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
18
|
22
|
47
|
55
|
|
| Other Long-Term Assets |
46
|
54
|
75
|
178
|
452
|
401
|
455
|
|
| Other Assets |
0
|
0
|
0
|
0
|
130
|
130
|
130
|
|
| Total Assets |
251
N/A
|
324
+29%
|
1 612
+397%
|
4 607
+186%
|
6 005
+30%
|
5 746
-4%
|
5 049
-12%
|
|
| Liabilities | ||||||||
| Accounts Payable |
13
|
17
|
59
|
119
|
293
|
147
|
90
|
|
| Accrued Liabilities |
14
|
28
|
55
|
106
|
272
|
116
|
132
|
|
| Short-Term Debt |
31
|
36
|
1
|
0
|
298
|
1 132
|
554
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
31
|
58
|
46
|
57
|
|
| Other Current Liabilities |
22
|
28
|
124
|
132
|
233
|
78
|
69
|
|
| Total Current Liabilities |
80
|
108
|
239
|
387
|
1 154
|
1 520
|
903
|
|
| Long-Term Debt |
0
|
0
|
0
|
60
|
128
|
107
|
143
|
|
| Deferred Income Tax |
0
|
0
|
0
|
1
|
11
|
2
|
1
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
3
|
0
|
2
|
|
| Other Liabilities |
5
|
16
|
40
|
32
|
100
|
89
|
57
|
|
| Total Liabilities |
85
N/A
|
124
+47%
|
279
+125%
|
480
+72%
|
1 396
+191%
|
1 717
+23%
|
1 103
-36%
|
|
| Equity | ||||||||
| Common Stock |
15
|
15
|
360
|
400
|
400
|
400
|
402
|
|
| Retained Earnings |
34
|
8
|
627
|
1 305
|
1 780
|
1 209
|
1 139
|
|
| Additional Paid In Capital |
185
|
193
|
345
|
2 422
|
2 429
|
2 442
|
2 512
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
20
|
104
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
2
|
4
|
|
| Total Equity |
166
N/A
|
200
+20%
|
1 332
+566%
|
4 127
+210%
|
4 609
+12%
|
4 029
-13%
|
3 945
-2%
|
|
| Total Liabilities & Equity |
251
N/A
|
324
+29%
|
1 612
+397%
|
4 607
+186%
|
6 005
+30%
|
5 746
-4%
|
5 049
-12%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
400
|
400
|
400
|
400
|
400
|
399
|
398
|
|
Switch to:
Switch to:
See Also
Discover More
